Key Financial Data Of Reporting Company

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7608022

Concept As at
2021-09-30
2021-04-01 to
2021-09-30
2021-07-01 to
2021-09-30
Key financial data of reporting company
Business results of reporting company
Net sales
28,477,000,000 JPY
Ordinary profit (loss)
2,743,000,000 JPY
Net assets
41,790,000,000 JPY
Total assets
78,295,000,000 JPY
Basic earnings (loss) per share
-98.52
-137.17
Diluted earnings per share
Equity-to-asset ratio
0.534 xbrli:pure
Net cash provided by (used in) operating activities
1,417,000,000 JPY
Net cash provided by (used in) investing activities
-427,000,000 JPY
Net cash provided by (used in) financing activities
-1,386,000,000 JPY
Cash and cash equivalents
10,117,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.